Table 3

Distribution of clinicopathological characteristics according to tumour origin in 175 re-evaluated periampullary adenocarcinomas
Duodenum Ampulla Intestinal type Ampulla Pancreatobiliary type Distal Bile Duct Pancreas All
n = 14 n = 51 n = 19 n = 45 n = 46 n = 175
Standardized Procedure 5 (36%) 7 (14%) 5 (26%) 18 (40%) 11 (24%) 46 (26%)
Age at surgery, M (IQR) 68 (62 – 74) 67 (59 – 70) 69 (62 – 75) 64 (59 – 71) 68 (62 – 72) 67 (61 – 72)
Gender, Female 6 (43%) 29 (57%) 9 (47%) 21 (47%) 21 (46%) 86 (49%)
Tumour size, mm, M (IQR) 40 (30 – 53) 23 (15–30) 30 (24 – 40) 26 (22 – 35) 30 (25 – 35) 30 (21 – 35)
 Larger than 20 mm 13 (93%) 27 (53%) 18 (95%) 37 (82%) 39 (85%) 134 (77%)
High grade 7 (50%) 26 (51%) 9 (47%) 31 (69%) 28 (61%) 101 (58%)
Lymph nodes, M (IQR) 10 (6 – 13.5) 9 (6 – 16) 10 (5 – 17) 12 (8 – 16.5) 11.5 (6.75 – 16) 11 (6 – 16)
 10 or more lymph nodes 8 (57%) 25 (49%) 10 (53%) 30 (67%) 27 (59%) 100 (57%)
Involved lymph nodes, M (IQR) 0 (0 – 2) 0 (0 – 2) 2 (1 – 7) 1 (0 – 4) 2 (0 – 3) 1 (0 – 3)
 pN1 4 (29%) 24 (47%) 16 (84%) 27 (60%) 34 (74%) 106 (61%)
 pN2 2 (14%)
Perineural infiltration 4 (29%) 16 (31%) 14 (74%) 37 (82%) 34 (74%) 105 (60%)
Infiltration in lymph vessels 2 (14%) 34 (67%) 15 (79%) 33 (73%) 27 (59%) 111 (63%)
Infiltration in blood vessels 0 (0.0%) 5 (10%) 8 (42%) 14 (31%) 15 (33%) 42 (24%)
Infiltration in peripancreatic fat 6 (43%) 16 (31%) 17 (89%) 36 (80%) 32 (70%) 107 (61%)
T-stage (pTNM)
T1 0 5 (10%) 0 1 (2%) 2 (4%)
T2 1 (7%) 11 (22%) 0 2 (4%) 10 (22%)
T3 6 (43%) 19 (37%) 2 (11%) 42 (93%) 34 (74%)
T4 7 (50%) 16 (31%) 17 (89%) 0 0
R1 3 (38%) 10 (43%) 14 (93%) 32 (89%) 35 (95%) 94 (79%)
R0 5 (63%) 13 (57%) 1 (7%) 4 (11%) 2 (6%) 25 (21%)
Rx,uncertain margin status (n) 6 28 4 9 9 56
Pancreatic transection margin 1 (13%) 1 (4%) 1 (7%) 5 (14%) 10 (27%) 18 (15%)
DBD transection margin 0 0 0 2 (6%) 1 (3%) 3 (3%)
SMA-margin 0 0 0 10 (28%) 2 (5%) 12 (10%)
Posterior margin 2 (25%) 6 (26%) 6 (40%) 17 (47%) 11 (30%) 42 (35%)
SMV-margin 1 (13%) 0 0 13 (36%) 18 (49%) 32 (27%)
Anterior margin 1 (13%) 1 (4%) 2 (13%) 5 (14%) 5 (14%) 14 (12%)
5-year OS, M (IQR), months n.r. (37 - n.r.) 53 (26 - n.r.) 26 (15–40) 25 (16 - n.r.) 25 (13–42) 30 (17-n.r.)

M, median. IQR, interquartile range. OS, overall survival. N.r., not reached.

Elebro and Jirström

Elebro and Jirström Diagnostic Pathology 2014 9:80   doi:10.1186/1746-1596-9-80

Open Data